Ocular melanoma: What's new?

Current Opinion in Oncology

Volumn 24, Issue 2, 2012, Pages 162-169

  Leyvraz, Serge ^a   Keilholz, Ulrich ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

GNA11; GNAQ; intra hepatic treatments; new molecular therapies; uveal melanoma

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DOXORUBICIN; EVEROLIMUS; FOTEMUSTINE; GANETESPIB; GEMCITABINE; HELIX LOOP HELIX PROTEIN; IMATINIB; IMMUNOGLOBULIN G1; IRINOTECAN; MELPHALAN; MITOMYCIN C; PACLITAXEL; PASIREOTIDE; SOMATOSTATIN; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TREOSULFAN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ARTERY PERFUSION; ARTIFICIAL EMBOLISM; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RISK; CHEMOEMBOLIZATION; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; EYE TUMOR; GENE EXPRESSION PROFILING; GENOME; HIGH RISK PATIENT; HUMAN; LIVER FUNCTION TEST; LIVER METASTASIS; LIVER PERFUSION; LIVER SUPPORT; MELANOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; UVEA MELANOMA;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; UVEAL NEOPLASMS;

EID: 84857039133     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834ff069     Document Type: Review

References (93)

1. Singh AD, Turell ME, Topham AK. Uveal melanoma: Trends in incidence, treatment, and survival. Ophthalmology 2011; 118:1881-1885; Epub 2011/ 06/28.
2. Virgili G, Gatta G, Ciccolallo L, et al. Incidence of uveal melanoma in Europe. Ophthalmology 2007; 114:2309-2315; Epub 2007/05/15.
3. Schmidt-Pokrzywniak A, Jockel KH, Bornfeld N, et al. Positive interaction between light iris color and ultraviolet radiation in relation to the risk of uveal melanoma: A case-control study. Ophthalmology 2009; 116:340-348; Epub 2008/12/19.
4. Shah CP, Weis E, Lajous M, et al. Intermittent and chronic ultraviolet light exposure and uveal melanoma: A meta-Analysis. Ophthalmology 2005; 112:1599-1607; Epub 2005/07/30. (Pubitemid 41725419)
5. Rimoldi D, Lemoine R, Kurt AM, et al. Detection of micrometastases in sentinel lymph nodes from melanoma patients: Direct comparison of multimarker molecular and immunopathological methods. Melanoma Res 2003; 13:511-520; Epub 2003/09/27. (Pubitemid 37266954)
6. Zuidervaart W, van Nieuwpoort F, Stark M, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 2005; 92:2032-2038; Epub 2005/06/02. (Pubitemid 40897426)
7. Onken MD, Worley LA, Long MD, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008; 49:5230-5234; Epub 2008/08/23.
8. Sisley K, Doherty R, Cross NA. What hope for the future? GNAQ and uveal melanoma. Br J Ophthalmol 2011; 95:620-623; Epub 2011/03/08. Good review on the mutations of GNAQ and downstream pathway activation, suggesting interesting therapeutic targets.
9. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457:599-602; Epub 2008/12/17.
10. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010 [Epub 2010/11/19]. After GNAQ mutations found in around 50% of primary uveal melanoma, description of other mutations in GNA11, mutually exclusive, in another 32% of primary tumors, conferring a dismal prognosis.
11. Bauer J, Kilic E, Vaarwater J, et al. Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer 2009; 101:813-815; Epub 2009/08/06.
12. Singh AD, Rennie IG, Seregard S, et al. Sunlight exposure and pathogenesis of uveal melanoma. Survey Ophthalmol 2004; 49:419-428; Epub 2004/07/ 03. (Pubitemid 38844800)
13. All-Ericsson C, Girnita L, Seregard S, et al. Insulin-like growth factor-1 receptor in uveal melanoma: A predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 2002; 43:1-8; Epub 2002/01/ 05. (Pubitemid 34032432)
14. Economou MA, All-Ericsson C, Bykov V, et al. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: Intercorrelation and prognostic implications. Invest Ophthalmol Vis Sci 2005; 46:4372-4375; Epub 2005/11/24. (Pubitemid 44264528)
15. Mallikarjuna K, Pushparaj V, Biswas J, Krishnakumar S. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: An immunohistochemical study. Curr Eye Res 2007; 32:281-290; Epub 2007/04/25. (Pubitemid 46439685)
16. Lefevre G,Glotin AL, Calipel A, et al. Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem 2004; 279:31769-31779; Epub 2004/05/18. (Pubitemid 39037849)
17. Luke J, Wegner J, Wegner R, et al. Expression of c-Kit and its ligand SCF in primary uveal melanoma. Eur J Ophthalmol 2011; 21:615-624; Epub 2011/ 02/01.
18. Pereira PR, Odashiro AN, Marshall JC, et al. The role of c-kit and imatinib mesylate in uveal melanoma. J Carcinogenesis 2005; 4:19; Epub 2005/10/ 21.
19. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330:1410-1413; Epub 2010/11/06. Implication of inactivation mutations of BRCA1-Associated protein 1 (BAP1), located on chromosome 3, in the metastatic process of uveal melanoma.
20. Prescher G, Bornfeld N, Becher R. Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Institute 1990; 82:1765-1769.
21. Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res 2010; 16:6083-6092; Epub 2010/10/27.
22. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64:7205-7209; Epub 2004/10/20. (Pubitemid 39372052)
23. Petrausch U, Martus P, Tonnies H, et al. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) 2008; 22:997-1007.
24. Trolet J, Hupe P, Huon I, et al. Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest Ophthalmol Vis Sci 2009; 50:2572-2580; Epub 2009/01/20.
25. Tschentscher F, Husing J, Holter T, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003; 63:2578-2584; Epub 2003/05/17. (Pubitemid 36608917)
26. Onken MD, Worley LA, Harbour JW. Association between gene expression profile, proliferation and metastasis in uveal melanoma. Curr Eye Res 2010; 35:857-863; Epub 2010/08/28.
27. Shields CL, Ganguly A, Bianciotto CG, et al. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology 2011; 118:396-401; Epub 2010/09/28.
28. Onken MD, Ehlers JP, Worley LA, et al. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res 2006; 66:4602-4609; Epub 2006/05/03.
29. Laurent C, Valet F, Planque N, et al. High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res 2011; 71:666-674; Epub 2010/12/08. After BAP1, another interesting gene located on chromosome 8 that is linked to a high metastatic risk and can be a potential candidate for therapy.
30. Makitie T, Summanen P, Tarkkanen A, Kivela T. Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci 1999; 40:2471-2480. (Pubitemid 29455473)
31. Bhat P, Jakobiec FA, Folberg R. Comparison of tumor-Associated vasculatures in uveal and cutaneous melanomas. Semin Ophthalmol 2009; 24:166-171.
32. Scholes AG, Damato BE, Nunn J, et al. Monosomy 3 in uveal melanoma: Correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci 2003; 44:1008-1011; Epub 2003/02/26. (Pubitemid 36297813)
33. Lagouros E, Salomao D, Thorland E, et al. Infiltrative T regulatory cells in enucleated uveal melanomas. Trans Am Ophthalmol Soc 2009; 107:223-228; Epub 2010/02/04.
34. Maat W, Ly LV, Jordanova ES, et al. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci 2008; 49:505-510; Epub 2008/02/01.
35. Herwig MC, Grossniklaus HE. Role of macrophages in uveal melanoma. Exp Rev Ophthalmol 2011; 6:405-407; Epub 2011/10/18.
36. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 2001; 42:1414-1421; Epub 2001/05/31. (Pubitemid 32520728)
37. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Investig 2007; 117:1155-1166; Epub 2007/ 05/04. (Pubitemid 46718400)
38. Bronkhorst IH, Ly LV, Jordanova ES, et al. Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci 2011; 52:643-650; Epub 2010/09/03.
39. Jager MJ, Ly LV, El Filali M, Madigan MC. Macrophages in uveal melanoma and in experimental ocular tumor models: Friends or foes? Prog Retinal Eye Res 2011; 30:129-146; Epub 2010/12/07.
40. Hawkins BS. Collaborative ocular melanoma study randomized trial of I-125 brachytherapy. Clin Trials 2011; 8:661-673; Epub 2011/10/21.
41. Caujolle JP,Mammar H, Chamorey E, et al. Proton beam radiotherapy for uveal melanomas at nice teaching hospital: 16 years' experience. Int J Radiat Oncol Biol Phys 2010; 78:98-103; Epub 2009/11/17.
42. Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C, et al. Treatment of uveal melanoma by accelerated proton beam. Develop Ophthalmol 2012; 49:41-57; Epub 2011/11/02. Results of a large group of patients treated by proton beam irradiation in a single institution with a prolonged follow-up for outcome and toxicity.
43. Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol 2009; 127:989-998; Epub 2009/08/12.
44. Damato B, Coupland SE. Translating uveal melanoma cytogenetics into clinical care. Arch Ophthalmol 2009; 127:423-429; Epub 2009/04/15.
45. Damato B, Duke C, Coupland SE, et al. Cytogenetics of uveal melanoma: A 7-year clinical experience. Ophthalmology 2007; 114:1925-1931; Epub 2007/08/28.
46. Damato B, Eleuteri A, Taktak AF, Coupland SE. Estimating prognosis for survival after treatment of choroidal melanoma. Progress in retinal and eye research 2011; 30:285-295; Epub 2011/06/11. Tool developed by the group of Liverpool to assess at best the prognosis of an individual patient according to his known clinical and genetic prognostic factors.
47. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 2005; 123:1639-1643; Epub 2005/12/14. (Pubitemid 41785095)
48. Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009; 148:119-127; Epub 2009/04/21.
49. Orcurto V, Denys A, Voelter V, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: Results from a pilot study. Melanoma Res 2011 [Epub 2011/10/27].
50. Servois V, Mariani P, Malhaire C, et al. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET). Eur J Surg Oncol 2010; 36:189-194; Epub 2009/09/25.
51. Lane AM, Egan KM, Harmon D, et al. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology 2009; 116:2206-2212; Epub 2009/09/12.
52. Voelter V, Schalenbourg A, Pampallona S, et al. Adjuvant intra-Arterial hepatic fotemustine for high-risk uveal melanoma patients. Melanoma Res 2008; 18:220-224; Epub 2008/05/15. (Pubitemid 351684668)
53. Kivela T, Eskelin S, Kujala E. Metastatic uveal melanoma. Int Ophthalmol Clin 2006; 46:133-149; Epub 2005/12/21. (Pubitemid 44124236)
54. Mariani P, Piperno-Neumann S, Servois V, et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol 2009; 35:1192-1197; Epub 2009/03/31.
55. Frenkel S, Nir I, Hendler K, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 2009; 93:1042-1046; Epub 2009/05/12.
56. Mavligit GM, Charnsangavej C, Carrasco CH, et al. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. J Am Med Assoc 1988; 260:974-976.
57. Huppert PE, Fierlbeck G, Pereira P, et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol 2010; 74:e38-44; Epub 2009/05/27.
58. Schuster R, Lindner M, Wacker F, et al. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: Toxicity and outcome. Melanoma Res 2010; 20:191-196; Epub 2010/03/26.
59. Dayani PN, Gould JE, Brown DB, et al. Hepatic metastasis from uveal melanoma: Angiographic pattern predictive of survival after hepatic arterial chemoembolization. Arch Ophthalmol 2009; 127:628-632; Epub 2009/05/ 13.
60. Vogl T, Eichler K, Zangos S, et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: Local tumor control and survival. J Cancer Res Clin Oncol 2007; 133:177-184; Epub 2006/10/06. (Pubitemid 46144093)
61. Sato T, Eschelman DJ, Gonsalves CF, et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2008; 26:5436-5442; Epub 2008/10/ 08.
62. Yamamoto A, Chervoneva I, Sullivan KL, et al. High-dose immunoembolization: Survival benefit in patients with hepatic metastases from uveal melanoma. Radiology 2009; 252:290-298; Epub 2009/06/30.
63. Fiorentini G, Aliberti C, Del Conte A, et al. Intra-Arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo 2009; 23:131-137; Epub 2009/04/17.
64. Kennedy AS, Nutting C, Jakobs T, et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 2009; 27:682-690; Epub 2009/02/17.
65. Gonsalves CF, Eschelman DJ, Sullivan KL, et al. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: A single-institution experience. Am J Roentgenol 2011; 196:468-473; Epub 2011/01/25.. The largest published study on the effect of radioembolization in 32 pretreated patients with impact of tumor burden on the antitumor effect and patient outcome. It might help to better choose patients with a high chance of response to this treatment.
66. Leyvraz S, Spataro V, Bauer J, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997; 15:2589-2595. (Pubitemid 27289889)
67. Peters S, Voelter V, Zografos L, et al. Intra-Arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: Experience in 101 patients. Ann Oncol 2006; 17:578-583; Epub 2006/02/14.
68. Siegel R, Hauschild A, Kettelhack C, et al. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol 2007; 33:627-632; Epub 2007/01/02. (Pubitemid 46746527)
69. Antoine RA. Technical considerations in percutaneous hepatic perfusion: A multicenter experience. J Extra-corporeal Technol 2011; 43:30-33; Epub 2011/04/01.
70. Alexander HR, Libutti SK, Bartlett DL, et al. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000; 6:3062-3070. (Pubitemid 30637729)
71. Alexander HR Jr., Libutti SK, Pingpank JF, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003; 9:6343-6349; Epub 2003/12/26. (Pubitemid 38031818)
72. Varghese S, Xu H, Bartlett D, et al. Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma. Ann Surg Oncol 2010; 17:1870-1877; Epub 2010/03/12.
73. Pingpank JF, Libutti SK, Chang R, et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 2005; 23:3465-3474; Epub 2005/05/24.
74. Pingpank JF, Hughes MS, Faries MB, et al. A phase III random assignment trials comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. J Clin Oncol 2010; 28(suppl; abstr LBA8512):18s. One of the few randomized trials in metastatic uveal melanoma, providing evidence of a biological efficacy of loco-regional therapy for the treatment of liver metastases, with an improved response rate and PFS. Unfortunately it did translate into improvement in overall survival, maybe due to cross-over.
75. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: A review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76:1665-1670.
76. Pons F, Plana M, Caminal JM, et al. Metastatic uveal melanoma: Is there a role for conventional chemotherapy? A single center study based on 58 patients. Melanoma Res 2011; 21:217-222; Epub 2011/04/07.
77. Schmittel A, Schmidt-Hieber M, Martus P, et al. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol 2006; 17:1826-1829; Epub 2006/09/15. (Pubitemid 44884059)
78. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723; Epub 2010/06/08.
79. Danielli R, Ridolfi R, Chiarion-Sileni V, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: Safety and clinical efficacy. Cancer Immunol Immunother 2011 [Epub 2011/08/13].
80. Tarhini AA, Moschos SJ, Tawbi H, et al. Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma. J Clin Oncol 2010; 28(suppl; abstr 8524):15s.
81. Garber K. Beyond ipilimumab: New approaches target the immunological synapse. J Natl Cancer Institute 2011; 103:1079-1082; Epub 2011/07/09.
82. Tarhini AA, Frankel P, Margolin KA, et al. Aflibercept (VEGF Trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin. Clin Cancer Res 2011; 17:6574-6581; Epub 2011/09/02. One of the first studies showing the effect of an antiangiogenic treatment in uveal melanoma.
83. Chan KR, Gundala S, Laudadio M, et al. A pilot study using sunitinib malate as therapy in patients with stage IV uveal melanoma. J Clin Oncol 2008; 26.
84. Kimple AJ, Bosch DE, Giguere PM, Siderovski DP. Regulators of G-protein signaling and their Galpha substrates: Promises and challenges in their use as drug discovery targets. Pharmacol Rev 2011; 63:728-749; Epub 2011/07/ 09.
85. Penel N, Delcambre C, Durando X, et al. O-Mel-Inib: A Cancero-pole Nord-Ouest multicenterphase II trial of high-dose imatinibmesylate in metastatic uveal melanoma. Investig New Drugs 2008; 26:561-565; Epub 2008/06/14.
86. Hofmann UB, Kauczok-Vetter CS, Houben R, Becker JC. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res 2009; 15:324-329; Epub 2009/01/02.
87. McKian KP, Haluska P. Cixutumumab. Exp Opin Investig Drugs 2009; 18:1025-1033 [Epub 2009/06/25].
88. Ardjomand N, Schaffler G, Radner H, El-Shabrawi Y. Expression of somatostatin receptors in uveal melanomas. Invest Ophthalmol Vis Sci 2003; 44:980-987; Epub 2003/02/26. (Pubitemid 36300757)
89. Abdel-Rahman MH, Boru G, Massengill J, et al. MET oncogene inhibition as a potential target of therapy for uveal melanomas. Invest Ophthalmol Vis Sci 2010; 51:3333-3339; Epub 2010/02/19.
90. Van Der Velden PA, De Lange M, Da Silva CG, et al.. C-Met signaling and preclinical analysis of Crizotinib in uveal melanoma. Acta Ophthalmol 2011; 89.
91. Lamba S, Felicioni L, Buttitta F, et al. Mutational profile of GNAQQ209 in human tumors. PloS One 2009; 4:e6833; Epub 2009/09/01.
92. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nature Rev Cancer 2010; 10:537-549; Epub 2010/07/ 24.
93. Faingold D, Marshall JC, Antecka E, et al. Immune expression and inhibition of heat shock protein 90 in uveal melanoma. Clin Cancer Res 2008; 14:847-855; Epub 2008/02/05. (Pubitemid 351231169)